

1 **Transcriptome-wide association study of risk of recurrence in Black and White breast cancer**
2 **patients**

3 Achal Patel¹, Montserrat García-Closas^{2,3}, Andrew F. Olshan^{1,4}, Charles M. Perou^{4,5,6}, Melissa A.
4 Troester^{1,6}, Michael I. Love^{5,7*}, Arjun Bhattacharya^{8*}

5

6 1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina-
7 Chapel Hill, Chapel Hill, NC, USA

8 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA

9 3. Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK

10 4. Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, USA

11 5. Department of Genetics, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA

12 6. Department of Pathology and Laboratory Medicine, University of North Carolina-Chapel Hill, Chapel
13 Hill, NC, USA

14 7. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina-
15 Chapel Hill, Chapel Hill, NC, USA

16 8. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of
17 California-Los Angeles, Los Angeles, CA, USA

18

19 *Correspondence can be directed to AB (abtbhatt@ucla.edu) and MIL (milove@email.unc.edu)

20

21 **ABSTRACT**

22 **Background:** Continuous risk of recurrence scores (CRS) based on PAM50 gene expression are vital
23 prognostic tools for breast cancer (BC). Studies have shown that Black women (BW) have higher CRS
24 than White women (WW). Although systemic injustices contribute substantially to BC disparities, evidence
25 for biological and germline contributions is emerging. We investigated germline genetic associations with
26 CRS and CRS disparity through a Transcriptome-Wide Association Study (TWAS).

27 **Methods:** In the Carolina Breast Cancer Study, using race-specific predictive models of tumor expression
28 from germline genetics, we performed race-stratified (N=1,043 WW, 1083 BW) linear regressions of three
29 CRS (ROR-S: PAM50 subtype score; Proliferation Score; ROR-P: ROR-S plus Proliferation Score) on
30 imputed Genetically-Regulated tumor eXpression (GReX). Using Bayesian multivariate regression and
31 adaptive shrinkage, we tested TWAS-significant genes for associations with PAM50 tumor expression
32 and subtype to elucidate patterns of germline regulation underlying TWAS-gene and CRS associations.

33 **Results:** At FDR-adjusted $P < 0.10$, we detected 7 TWAS-genes among WW and 1 TWAS-gene among
34 BW. Among WW, CRS showed positive associations with *MCM10*, *FAM64A*, *CCNB2*, and *MMP1* GReX
35 and negative associations with *VAV3*, *PCSK6*, and *GNG11* GReX. Among BW, higher *MMP1* GReX
36 predicted lower Proliferation score and ROR-P. TWAS-gene and PAM50 tumor expression associations
37 highlighted potential mechanisms for TWAS-gene to CRS associations.

38 **Conclusions:** Among BC patients, we find differential germline associations with three CRS by race,
39 underscoring the need for larger, more diverse datasets in molecular studies of BC. Our findings also
40 suggest possible germline *trans*-regulation of PAM50 tumor expression, with potential implications for
41 interpreting CRS in clinical settings.

42

43 **Keywords:** breast cancer recurrence, risk of recurrence, transcriptome-wide association study, molecular
44 subtype, trans-eQTL mapping

45 **ABBREVIATIONS**

46	BC	Breast Cancer
47	BW	Black Women
48	CBCS	Carolina Breast Cancer Study
49	CRS	Continuous Risk of recurrence Score
50	eQTL	expression Quantitative Trait Locus
51	ER	Estrogen Receptor
52	GRex	Genetically-Regulated tumor eXpression
53	GWAS	Genome-Wide Association Study
54	HR	Hormone Receptor
55	LumA	Luminal A
56	LumB	Luminal B
57	ROR	Risk of Recurrence
58	SCC	Subtype-Centroid Correlations
59	SNP	Single Nucleotide Polymorphism
60	TCGA	The Cancer Genome Atlas
61	TWAS	Transcriptome-Wide Association Study
62	WW	White Women

63 **INTRODUCTION (Manuscript Word Count = 3000)**

64 Tumor expression-based molecular profiling has improved clinical classification of breast cancer
65 (BC) [1-3]. One tool is the PAM50 assay which integrates tumor expression of 50 genes (from
66 approximately 1,900 “intrinsic” genes identified through microarray) to determine intrinsic molecular
67 subtypes: Luminal A (LumA), Luminal B (LumB), Human epidermal growth factor 2-enriched (HER2-
68 enriched), Basal-like, Normal-like [1, 4]. Continuous risk of recurrence scores (CRS) generated from
69 PAM50 tumor expression have prognostic value in clinical settings. [5-7]. For node negative, hormone
70 receptor (HR) positive/HER2 negative BC, ROR-PT (a CRS determined by PAM50-subtype score,
71 PAM50-based Proliferation score, and tumor size) offers overall and late distant recurrence information;
72 other multigene signatures (OncotypeDx and EPclin) provide similar prognostic information for clinical
73 decision-making [7, 8].

74 In the Carolina Breast Cancer Study (CBCS), Black women (BW) with breast cancer have
75 disproportionately higher CRS than White Women [9], with similar disparities in Oncotype Dx recurrence
76 score [9, 10]. Systemic injustices, like disparities in healthcare access, explain a substantial proportion of
77 breast cancer outcome disparities [11-14], but recent studies suggest germline genetic variation may also
78 play a role in outcome disparity. In The Cancer Genome Atlas (TCGA), BW had substantially higher
79 polygenic risk scores for the more aggressive ER-negative subtype than WW, suggesting differential
80 genetic contributions towards BC and especially ER-negative BC incidence [15]. In a transcriptome-wide
81 association study (TWAS) of BC mortality, germline-regulated gene expression of four genes was
82 associated with mortality among BW and none associated among WW [16]. However, the role of germline
83 genetic variation in relation to CRS and CRS disparity remains an important knowledge gap.

84 As racially-diverse genetic datasets typically have small samples of BW, gene-level association
85 tests can be used to increase study power. These approaches include TWAS, which integrates
86 relationships between single nucleotide polymorphisms (SNP) and gene expression with genome-wide
87 association studies (GWAS) to prioritize gene-trait associations [17, 18]. TWAS has identified cancer
88 susceptibility genes at loci previously undetected through GWAS, highlighting its improved power and
89 interpretability [19-21]. Previous studies show that stratification of the entire TWAS (model training,

90 imputation, and association testing) is preferable in diverse populations, as models may perform poorly
91 across ancestry groups and methods for TWAS in admixed populations are unavailable [16, 22].

92 Here, using data from the CBCS, which includes a large sample of Black BC patients with tumor
93 gene expression data, we study race-specific germline genetic associations for CRS using TWAS. CRS
94 included in this study are ROR-S (PAM50 subtype score), PAM50-based Proliferation score, and ROR-P
95 (ROR-S + Proliferation score). Using race-specific predictive models for tumor expression from germline
96 genetics, we identify sets of TWAS-genes associated with these CRS across BW and WW. We
97 additionally investigate TWAS-genes for ROR-P for associations with PAM50 subtype and subtype-
98 specific tumor gene expressions to elucidate germline contributions to PAM50 subtype, and how these
99 mediate TWAS-gene and CRS associations. Unlike previous studies that correlated tumor gene
100 expression (as opposed to germline-regulated tumor gene expression) with subtype or subtype-specific
101 tumor gene expressions, TWAS enables directional interpretation of observed associations by ruling out
102 reverse causality [17, 18].

103

104 **METHODS**

105 ***Data collection***

106 *Study population*

107 The CBCS is a population-based study of North Carolina BC patients with three phases; study
108 details have been previously described [23, 24]. Patients aged 20 to 74 were identified using rapid case
109 ascertainment with the NC Central Cancer Registry with randomized recruitment to oversample self-
110 identified Black and young women (ages 20-49) [9, 24]. Demographic and clinical data (age, menopausal
111 status, body mass index, hormone receptor status, tumor stage, study phase, recurrence) were obtained
112 through questionnaires and medical records. Recurrence data were available for CBCS Phase 3. The
113 study was approved by the Office of Human Research Ethics at the University of North Carolina at
114 Chapel Hill, and informed consent was obtained from each participant.

115

116 *CBCS genotype data*

117 Genotypes were assayed on the OncoArray Consortium's custom SNP array (Illumina Infinium
118 OncoArray) [25] and imputed using the 1000 Genomes Project (v3) as a reference panel for two-step
119 phasing and imputation using SHAPEIT2 and IMPUTEv2 [26-29]. The DCEG Cancer Genomics
120 Research Laboratory conducted genotype calling, quality control, and imputation [25]. We excluded
121 variants with less than 1% minor allele frequency and deviations from Hardy-Weinberg equilibrium at
122 $P < 10^{-8}$ [30, 31]. We intersected genotyping panels for BW and WW samples, resulting in 5,989,134
123 autosomal variants and 334,391 variants on the X chromosome [32].

124

125 *CBCS gene expression data*

126 Paraffin-embedded tumor blocks were assayed for gene expression of 406 BC-related and 11
127 housekeeping genes using NanoString nCounter at the Translational Genomics Laboratory at UNC-
128 Chapel Hill [4, 9]. As described previously, we eliminated samples with insufficient data quality using
129 NanoStringQCPro [16, 33], scaled distributional difference between lanes with upper-quartile
130 normalization [34], and removed two dimensions of unwanted technical and biological variation, estimated
131 from housekeeping genes using RUVSeq [34, 35]. The current analysis included 1,199 samples with both
132 genotype and gene expression data (628 BW, 571 WW).

133

134 **Statistical analysis**

135 *Overview of TWAS*

136 TWAS integrates expression data with GWAS to prioritize gene-trait associations through a two-
137 step analysis (**Figure 1A-B**). First, using genetic and transcriptomic data, we trained predictive models of
138 tumor gene expression using all SNPs within 0.5 Megabase of the gene [16, 18]. Second, we used these
139 models to impute expression into an external GWAS panel to generate the Genetically-Regulated tumor
140 eXpression (GReX) of a gene. This quantity represents the portion of tumor expression explained by *cis*-
141 genetic regulation and is used to test for gene-trait associations with an outcome. By focusing on
142 genetically regulated expression, TWAS avoids instances of expression-trait association that are not
143 consequences of genetic variation but are driven by the effect of traits on expression. If sufficiently

144 heritable genes are assayed in the correct tissue, TWAS increases power to detect gene-trait
145 associations and aids interpretability of results, as associations are mapped to individual genes [18, 36].

146

147 *CRS TWAS in CBCS*

148 We adopted techniques from FUSION to train predictive models of tumor expression from *cis*-
149 germline genotypes, as discussed previously [16, 18]. Motivated by strong associations between germline
150 genetics and tumor expression in CBCS [16], for genes with non-zero *cis*-heritability at nominal $P < 0.10$,
151 we trained predictive models for covariate-residualized tumor expression with all *cis*-SNPs within 0.5
152 Megabase using linear mixed modeling or elastic net regression (**Supplementary Methods,**
153 **Supplementary Materials**). We selected models with five-fold cross-validation adjusted $R^2 > 0.01$
154 between predicted and observed expression values, resulting in 59 and 45 models for WW and BW,
155 respectively (**Supplementary Data**). Using only germline genetics as an input, we imputed GReX in
156 1,043 WW and 1,083 BW, respectively, in CBCS; for samples in both the training and imputation
157 samples, GReX was imputed via cross-validation to minimize data leakage. We tested GReX for
158 associations with ROR-S, Proliferation Score, and ROR-P using multiple linear regression adjusted for
159 age, estrogen receptor (ER) status, tumor stage, and study phase [1]. We corrected for test-statistic bias
160 and inflation using *bacon* and adjusted for multiple testing using the Benjamini-Hochberg procedure [37,
161 38]. To compare germline effects with total (germline and post-transcriptional) effects on ROR, we
162 assessed relationships between tumor expression of TWAS genes and CRS using similar linear models.
163 We were underpowered to study time-to-recurrence due to small sample size, as recurrence data was
164 collected only in CBCS Phase 3 (635 WW, 742 BW with GReX and recurrence data; 183 WW, 283 BW
165 with tumor expression and recurrence data).

166

167 *PAM50 assay and ROR-S, Proliferation score, and ROR-P calculation*

168 Using partition-around-medoid clustering, we calculated correlation with each subtype's centroid
169 for study individuals based on PAM50 expressions (10 PAM50 genes per subtype); the largest subtype-
170 centroid correlation defined the individual's molecular subtype [1]. ROR-S was determined via linear
171 combination of the PAM50 subtype-centroid correlations (SCCs) [1]. Proliferation score was computed

172 using log-scale expression of 11 PAM50 genes while ROR-P was computed by combining ROR-S and
173 Proliferation score.

174

175 *Bayesian multivariate regressions and multivariate adaptive shrinkage*

176 To better understand germline *trans*-regulation of PAM50 tumor gene expression and germline
177 contribution to subtype, and to understand how these mediate TWAS-gene and CRS associations, we
178 assessed TWAS-genes (for ROR-P) in relation to SCCs and PAM50 tumor gene expressions (**Figure**
179 **1C**). We found that none of our TWAS-genes were within 1 Megabase of PAM50 genes and that most
180 TWAS-genes were not on the same chromosome as PAM50 genes (**Supplementary Table S1**). Existing
181 gene-based mapping techniques for *trans*-expression quantitative trait loci (eQTL) (SNP and gene are
182 separated by more than 1 Megabase) mapping include *trans*-PrediXcan and GBAT [39, 40]. We
183 employed Bayesian multivariate linear regression (BtQTL) to account for correlation in multivariate
184 outcomes (SCCs and PAM50 gene expression) in association testing. BtQTL improves power to detect
185 significant *trans*-associations, especially when considering multiple genes with highly correlated (>0.5)
186 expression (**Supplementary Methods, Supplementary Figures S1-S2, Supplementary Materials**).
187 Lastly, we conducted adaptive shrinkage on BtQTL estimates using mashr, an empirical Bayes method to
188 estimate patterns of similarity and improve accuracy in associations tests across multiple outcomes [41].
189 mashr outputs revised posterior means, standard deviations, and corresponding measures of significance
190 (local false sign rates).

191

192 **RESULTS**

193 **Association between GReX and risk of recurrence scores**

194 We performed race-specific TWAS for CRS to investigate the role of germline genetic variation in
195 CRS and CRS racial disparity. We identified 8 genes (*MCM10*, *FAM64A*, *CCNB2*, *MMP1*, *VAV3*, *PCSK6*,
196 *NDC80*, *MLPH*), 8 genes (*MCM10*, *FAM64A*, *CCNB2*, *MMP1*, *VAV3*, *NDC80*, *MLPH*, *EXO1*), and 10
197 genes (*MCM10*, *FAM64A*, *CCNB2*, *MMP1*, *VAV3*, *PCSK6*, *GNG11*, *NDC80*, *MLPH*, *EXO1*) whose GReX
198 was associated with ROR-S, proliferation, and ROR-P, respectively, in WW, and 1 gene (*MMP1*) whose
199 GReX was associated with proliferation and ROR-P in BW at FDR-adjusted $P < 0.10$ (**Figure 2A, 2B**). No

200 associations were detected between GReX and ROR-S among BW. We refer to genes with statistically
201 significant TWAS associations (FDR-adjusted $P < 0.10$) as TWAS-genes. Among these identified genes,
202 only genes that are not part of the PAM50 panel (i.e., excluding *NDC80*, *MLPH*, *EXO1*) were considered
203 in downstream permutation and TWAS-gene follow up analyses (**Figure 1C**), as we wished to focus
204 investigation on relationship between non-PAM50 TWAS-genes and PAM50 (tumor) genes.

205 Among WW, increased GReX of *MCM10*, *FAM64A*, *CCNB2*, and *MMP1* were associated with
206 higher CRS while increased GReX of *VAV3*, *PCSK6*, and *GNG11* were associated with lower CRS
207 (**Figure 2A**). Among BW, increased GReX of *MMP1* was associated with lower CRS (Proliferation, ROR-
208 P, but not ROR-S) (**Figure 2A**). To provide statistical context for variance in CRS explained by significant
209 TWAS-genes, we permuted covariate-residualized CRS to generate a null distribution for adjusted R^2
210 between TWAS-genes and CRS. Across WW and BW, the observed R^2 of TWAS-genes against CRS (7-
211 10% among WW and 1% among BW) were statistically significant against the respective null distributions
212 ($P < 0.001$ among WW and $P < 0.05$ among BW) (**Figure 2B**).

213 Associations between tumor expression of TWAS-genes and CRS were concordant, in terms of
214 direction of association to germline-only effects among WW; findings were discordant among BW
215 (**Supplementary Table S2-S3**). Permutation tests for analyses of tumor expression of TWAS-genes and
216 CRS are available in **Supplementary Figure S3**.

217

218 **Associations between TWAS-genes and breast cancer molecular subtype**

219 Among WW, a one standard deviation increase in *FAM64A* and *CCNB2* GReX resulted in
220 significantly increased Basal-like SCC while an identical increase in *VAV3*, *PCSK6*, and *GNG11* resulted
221 in significantly increased Luminal A SCC. The magnitude of increase in correlation for respective
222 subtypes per GReX gene was approximately 0.05, and most estimates had credible intervals that did not
223 intersect the null. Among WW, associations between HER2-like SCC and GReX followed similar patterns
224 to associations for the Basal-like subtype, although associations for HER2 were more precise (**Figure**
225 **3A**). We found predominantly null associations for GReX for Luminal B SCC among WW (**Figure 3A**).
226 Unlike in WW, for BW, an increase in *MMP1* GReX was not associated with Luminal A, HER2 or Basal-

227 like SCCs. Instead, among BW, *MMP1* GReX was significantly negatively associated with Luminal B
228 SCC. Estimates from univariate regressions are provided in **Supplementary Tables S4-S7**.

229

230 **Association between TWAS-genes and PAM50 gene expression**

231 For both WW and BW, the pattern of associations between significant GReX and PAM50 tumor
232 expression were predominantly congruent with observed associations for SCCs and CRS (**Figure 4**). In
233 WW, a one standard deviation increase in *CCNB2* GReX was associated with significantly increased
234 *ORC6L*, *PTTG1*, and *KIF2C* (Basal-like genes) expression and *UBE2T*, *MYBL2* (LumB genes)
235 expression. By contrast, a one standard deviation increase in *PCSK6* GReX significantly increased
236 *BAG1*, *FOXA1*, *MAPT*, and *NAT1* (LumA genes) expression (**Figure 4**). While increased *MMP1* GReX
237 was associated with significantly increased expression of *ORC6L* (basal-like gene), *MYBL2*, and *BIRC5*
238 (LumB genes) among WW, this was not the case among BW. Instead, increased *MMP1* GReX among
239 BW was significantly associated with increased expression of *SLC39A6* (LumA gene) and decreased
240 expression of *ACTR3B*, *PTTG1*, and *EXO1* (Basal-like genes) (**Figure 4**). **Supplementary Tables S8-**
241 **S11** and **Figure 4** provide all TWAS-gene and PAM50 gene expression associations across WW and
242 BW.

243

244 **DISCUSSION**

245 Through TWAS, we identified 7 and 1 genes among WW and BW, respectively, for which GReX
246 was associated with CRS and underlying PAM50 expressions and subtype. Among WW, these 7 TWAS-
247 genes explained between 7-10% of the variation in CRS, a large and statistically significant proportion of
248 variance. Among BW, the singular TWAS-gene explained ~1% of the variation in Proliferation score and
249 ROR-P. Differences in the number and effect of identified TWAS-genes by race may point to factors that
250 warrant further investigation: (1) potentially greater contribution of *trans*-regulation in tumor gene
251 expression in BW, as shown previously, and (2) potential racial differences in tumor methylation and
252 somatic alternations, which could not be accounted for in CBCS[16, 42-47].

253 There are two key novel aspects to this study. First, existing literature on associations between
254 tumor gene expression and recurrence (for which CRS are a proxy) cannot distinguish between genetic

255 and non-genetic component of effects [48]. Second, TWAS allows causal interpretation of observed
256 associations. For instance, prior studies report *CCNB2* is upregulated in triple-negative breast cancers
257 (TNBC) but were unable to determine whether increased *CCNB2* expression contributes to development
258 or maintenance of TNBC or is part of the molecular response to cancer progression [49, 50]. By contrast,
259 GReX is a function of only genetic variation. Thus, TWAS allows causal interpretation, subject to effective
260 control for population stratification and minimal horizontal pleiotropy [17, 18].

261 Our WW-specific finding that prioritizes *MCM10*, *FAM64A*, and *CCNB2* associations with Basal-
262 like and HER2-enriched subtypes and subtype-specific gene expressions are consistent with literature.
263 Prior investigations in cohorts of primarily European ancestry have reported that *MCM10*, *FAM64A*, and
264 *CCNB2* expression is higher in ER-negative than ER-positive tumors [49-51]. In studies that compared
265 triple-negative and non-triple negative subtypes, higher *MCM10*, *FAM64A*, and *CCNB2* expression was
266 detected in triple-negative BC [49, 50]. Histologically, HER2-enriched and Basal-like subtypes are
267 typically ER-negative, and triple-negatives are similar to Basal-like subtypes [9, 52]. *MCM10*, *FAM64A*,
268 and *CCNB2* are all implicated in cell cycle processes, including DNA replication [51, 53, 54]. Our WW-
269 specific findings that GReX of *PCSK6* and *VAV3* associated with Luminal A and Luminal A specific gene
270 expressions are also consistent with previous results of *PCSK6* and *VAV3* upregulation in ER-positive
271 subtypes [55, 56].

272 Presently, little is known about germline genetic regulation of PAM50 tumor expression. In CBCS,
273 we found that tumor expression of most PAM50 genes is not *cis*-heritable. Instead, observed TWAS-gene
274 and PAM50 gene expression associations may implicate *trans*-gene regulation of the PAM50 signature.
275 For instance, we found that *VAV3* GReX is significantly positively associated with tumor expression of
276 *BAG1*, *FOXA1*, *MAPT*, and *NAT1* and nominally with increased tumor *ESR1* expression, all of which are
277 Luminal A-specific genes. Such *trans*-genic regulation signals, especially in the case of *ESR1*, pose
278 significant clinical and therapeutic implication if confirmed under experimental conditions. For example,
279 *VAV3* activates *RAC1* which upregulates *ESR1* but such mechanistic evidence is sparse for other
280 putative TWAS-gene to PAM50 gene associations [57, 58]. More generally, two of the TWAS-genes
281 among WW (*FAM64A*, *PCSK6*) have been found to activate the oncogenic *STAT3* signaling pathway,
282 housing many purported anti-cancer drug targets [59, 60].

283 Interestingly, we found *MMP1* GReX has divergent associations with ROR across race. There are
284 a few potential explanations. First, the range of *MMP1* GReX was manifold among WW than BW,
285 suggesting sparser *cis*-eQTL architecture of *MMP1* in BW and more influence from *trans*-acting signals.
286 Potential differences in influence of germline genetics on tumor expression and ROR by race could be an
287 artifact of divergent somatic or epigenetic factors that CBCS has not assayed [44-47]. Second, while
288 studies generally report that *MMP1* tumor expression is higher in triple-negative and Basal-like breast
289 cancer, one study reported that *MMP1* expression in tumor cells does not significantly differ by subtype
290 [61-63]. Instead, Bostrom *et al.* reported that *MMP1* expression differs in stromal cells of patients with
291 different subtypes [63]. There is evidence to suggest that tumor composition, including stromal and
292 immune components, may influence BC progression in a subtype-specific manner and future studies
293 should consider expression predictive models that integrate greater detail on tumor cell-type composition
294 [64, 65].

295 There are a few limitations to this study. First, as CBCS used a custom Nanostring nCounter
296 probeset for mRNA expression quantification, we could not analyze the whole human transcriptome.
297 While this probeset may exclude several *cis*-heritable genes, CBCS contains one of the largest breast
298 tumor transcriptomic datasets for Black women, allowing us to build well-powered race-specific predictive
299 models, a pivotal step in transethnic TWAS. Second, CBCS lacked data on somatic amplifications and
300 deletions, inclusion of which could enhance the performance of predictive models [66]. Third, as
301 recurrence data was collected in a small subset with few recurrence events, we were unable to make a
302 direct comparison between CRS and recurrence results, which may affect clinical generalizability.
303 However, to our knowledge, CBCS is the largest resource of PAM50-based CRS data.

304 Our analysis provides evidence of putative CRS and germline variation associations in breast
305 tumors across race, motivating larger diverse cohorts for genetic epidemiology studies of breast cancer.
306 Future studies should consider subtype-specific TWAS (i.e., stratification by subtype in predictive model
307 training and association analyses) to elucidate heritable gene expression effects on breast cancer
308 outcomes both across and within subtype, which may yield further hypotheses for more fine-tuned clinical
309 intervention.

310

311 **FUNDING**

312 This work was supported by Susan G. Komen® for the Cure for CBCS study infrastructure.
313 Funding was provided by the National Institutes of Health, National Cancer Institute P01-CA151135, P50-
314 CA05822, and U01-CA179715 to AFO, CMP, and MAT. AP is supported by T32ES007018. MIL is
315 supported by R01-HG009937, R01-MH118349, P01-CA142538, and P30-ES010126. The Translational
316 Genomics Laboratory is supported in part by grants from the National Cancer Institute (3P30CA016086)
317 and the University of North Carolina at Chapel Hill University Cancer Research Fund. Genotyping was
318 done at the DCEG Cancer Genomics Research Laboratory using funds from the NCI Intramural Research
319 Program.

320 Funding for BCAC and iCOGS came from: Cancer Research UK [grant numbers C1287/A16563,
321 C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007,
322 C5047/A10692, C8197/A16565], the European Union's Horizon 2020 Research and Innovation
323 Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), the European
324 Community's Seventh Framework Programme under grant agreement n° 223175 [HEALTHF2-2009-
325 223175] (COGS), the National Institutes of Health [CA128978] and Post-Cancer GWAS initiative [1U19
326 CA148537, 1U19 CA148065-01 (DRIVE) and 1U19 CA148112 - the GAME-ON initiative], the Department
327 of Defence [W81XWH-10-1-0341], and the Canadian Institutes of Health Research CIHR) for the CIHR
328 Team in Familial Risks of Breast Cancer [grant PSR-SIIRI-701]. All studies and funders as listed in
329 Michailidou K *et al* (2013 and 2015) and in Guo Q *et al* (2015) are acknowledged for their contributions.

330
331 **NOTES**

332 *Affiliations of authors:* Department of Epidemiology, Gillings School of Global Public Health (AP, AFO,
333 MAT), Department of Biostatistics (MIL), Department of Genetics (MIL, CMP), Department of Pathology
334 and Laboratory Medicine (MAT, CMP), Lineberger Comprehensive Cancer Center (AFO, CMP),
335 University of North Carolina at Chapel Hill; Department of Pathology and Laboratory Medicine, David
336 Geffen School of Medicine, University of California, Los Angeles (AB); Division of Cancer Epidemiology
337 and Genetics, National Cancer Institute (MG); Division of Genetics and Epidemiology, Institute of Cancer
338 Research (MG)

339

340 *Prior presentation:* This work has been presented in poster sessions at the 2020 American Association for
341 Cancer Research: The Science of Cancer Health Disparities and the 2020 Harvard Population
342 Quantitative Genetics conferences.

343

344 *Disclaimers:* CMP is an equity stock holder, consultant, and board of directors member of BioClassifier
345 LLC and GeneCentric Diagnostics. CMP is also listed as an inventor on patent applications on the Breast
346 PAM50 assay.

347

348 *Role of the funder:* This content is solely the responsibility of the authors and does not necessarily
349 represent the official views of the National Institutes of Health. The funder had no role in study design,
350 data collection, analysis or interpretation, or writing of the manuscript.

351

352 *Acknowledgements:* We thank the Carolina Breast Cancer Study participants and volunteers. We also
353 thank Colin Begg, Jianwen Cai, Katherine Hoadley, Yun Li, and Bogdan Pasaniuc for valuable discussion
354 during the research process. We thank Erin Kirk and Jessica Tse for their invaluable support during the
355 research process. We thank the DCEG Cancer Genomics Research Laboratory and acknowledge the
356 support from Stephen Chanock, Rose Yang, Meredith Yeager, Belynda Hicks, and Bin Zhu. We also
357 acknowledge the iCOGs Consortium for their publicly available GWAS summary statistics.

358

359 **AVAILABILITY OF DATA AND MATERIALS**

360 Expression data from CBCS is available on NCBI GEO with accession number GSE148426.
361 CBCS genotype datasets analyzed in this study are not publicly available as many CBCS patients are still
362 being followed and accordingly CBCS data is considered sensitive; the data is available from M.A.T upon
363 reasonable request. Supplementary Data includes summary statistics for eQTL results, tumor expression
364 models, and relevant R code for training expression models in CBCS and are freely available
365 at https://github.com/bhattacharya-a-bt/CBCS_TWAS_Paper/. iCOGs summary statistics are available
366 online at <http://bcac.ccge.medschl.cam.ac.uk/bcacdata/icogs-complete-summary-results>.

367 **REFERENCES**

- 368 1. Parker JS, Mullins M, Cheang MC, *et al.* Supervised risk predictor of breast cancer based on
369 intrinsic subtypes. *J Clin Oncol* 2009;27(8):1160-7.
- 370 2. Wallden B, Storhoff J, Nielsen T, *et al.* Development and verification of the PAM50-based
371 Prosigna breast cancer gene signature assay. *BMC Med Genomics* 2015;8:54.
- 372 3. Paik S, Shak S, Tang G, *et al.* A multigene assay to predict recurrence of tamoxifen-treated,
373 node-negative breast cancer. *N Engl J Med* 2004;351(27):2817-26.
- 374 4. Geiss GK, Bumgarner RE, Birditt B, *et al.* Direct multiplexed measurement of gene expression
375 with color-coded probe pairs. *Nat Biotechnol* 2008;26(3):317-25.
- 376 5. Harris LN, Ismaila N, McShane LM, *et al.* Use of Biomarkers to Guide Decisions on Adjuvant
377 Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical
378 Oncology Clinical Practice Guideline. *Journal of Clinical Oncology* 2016;34(10):1134-1150.
- 379 6. Coates AS, Winer EP, Goldhirsch A, *et al.* Tailoring therapies--improving the management of
380 early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast
381 Cancer 2015. *Ann Oncol* 2015;26(8):1533-46.
- 382 7. Dowsett M, Sestak I, Lopez-Knowles E, *et al.* Comparison of PAM50 Risk of Recurrence Score
383 With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. *Journal*
384 *of Clinical Oncology* 2013;31(22):2783-2790.
- 385 8. Sestak I, Buus R, Cuzick J, *et al.* Comparison of the Performance of 6 Prognostic Signatures for
386 Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA*
387 *Oncol* 2018;4(4):545-553.
- 388 9. Troester MA, Sun X, Allott EH, *et al.* Racial Differences in PAM50 Subtypes in the Carolina
389 Breast Cancer Study. *J Natl Cancer Inst* 2018;110(2):176-82.
- 390 10. Albain KS, Gray RJ, Makower DF, *et al.* Race, ethnicity and clinical outcomes in hormone
391 receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. *J Natl*
392 *Cancer Inst* 2020; 10.1093/jnci/djaa148.
- 393 11. Reeder-Hayes KE, Anderson BO. Breast Cancer Disparities at Home and Abroad: A Review of
394 the Challenges and Opportunities for System-Level Change. *Clin Cancer Res* 2017;23(11):2655-2664.

- 395 12. Durham DD, Robinson WR, Lee SS, *et al.* Insurance-Based Differences in Time to Diagnostic
396 Follow-up after Positive Screening Mammography. *Cancer Epidemiol Biomarkers Prev* 2016;25(11):1474-
397 1482.
- 398 13. Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes:
399 biological, social, and health system determinants and opportunities for research. *Oncologist*
400 2013;18(9):986-93.
- 401 14. Ko NY, Hong S, Winn RA, *et al.* Association of Insurance Status and Racial Disparities With the
402 Detection of Early-Stage Breast Cancer. *JAMA Oncology* 2020;6(3):385-392.
- 403 15. Huo D, Hu H, Rhie SK, *et al.* Comparison of Breast Cancer Molecular Features and Survival by
404 African and European Ancestry in The Cancer Genome Atlas. *JAMA Oncol* 2017;3(12):1654-1662.
- 405 16. Bhattacharya A, García-Closas M, Olshan AF, *et al.* A framework for transcriptome-wide
406 association studies in breast cancer in diverse study populations. *Genome Biol* 2020;21(1):42.
- 407 17. Gamazon ER, Wheeler HE, Shah KP, *et al.* A gene-based association method for mapping traits
408 using reference transcriptome data. *Nat Genet* 2015;47(9):1091-8.
- 409 18. Gusev A, Ko A, Shi H, *et al.* Integrative approaches for large-scale transcriptome-wide
410 association studies. *Nat Genet* 2016;48(3):245-52.
- 411 19. Zhong J, Jermusyk A, Wu L, *et al.* A Transcriptome-Wide Association Study Identifies Novel
412 Candidate Susceptibility Genes for Pancreatic Cancer. *J Natl Cancer Inst* 2020;112(10):1003-1012.
- 413 20. Wu L, Shi W, Long J, *et al.* A transcriptome-wide association study of 229,000 women identifies
414 new candidate susceptibility genes for breast cancer. *Nat Genet* 2018;50(7):968-978.
- 415 21. Mancuso N, Gayther S, Gusev A, *et al.* Large-scale transcriptome-wide association study
416 identifies new prostate cancer risk regions. *Nat Commun* 2018;9(1):4079.
- 417 22. Keys KL, Mak ACY, White MJ, *et al.* On the cross-population generalizability of gene expression
418 prediction models. *PLoS Genet* 2020;16(8):e1008927.
- 419 23. Hair BY, Hayes S, Tse CK, *et al.* Racial differences in physical activity among breast cancer
420 survivors: implications for breast cancer care. *Cancer* 2014;120(14):2174-82.
- 421 24. Newman B, Moorman PG, Millikan R, *et al.* The Carolina Breast Cancer Study: integrating
422 population-based epidemiology and molecular biology. *Breast Cancer Res Treat* 1995;35(1):51-60.

- 423 25. Amos CI, Dennis J, Wang Z, *et al.* The OncoArray Consortium: A Network for Understanding the
424 Genetic Architecture of Common Cancers. *Cancer Epidemiol Biomarkers Prev* 2017;26(1):126-135.
- 425 26. Auton A, Brooks LD, Durbin RM, *et al.* A global reference for human genetic variation. *Nature*
426 2015;526(7571):68-74.
- 427 27. O'Connell J, Gurdasani D, Delaneau O, *et al.* A general approach for haplotype phasing across
428 the full spectrum of relatedness. *PLoS Genet* 2014;10(4):e1004234.
- 429 28. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of
430 genomes. *Nat Methods* 2011;9(2):179-81.
- 431 29. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the
432 next generation of genome-wide association studies. *PLoS Genet* 2009;5(6):e1000529.
- 433 30. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. *Am*
434 *J Hum Genet* 2005;76(5):887-93.
- 435 31. Purcell S, Neale B, Todd-Brown K, *et al.* PLINK: a tool set for whole-genome association and
436 population-based linkage analyses. *Am J Hum Genet* 2007;81(3):559-75.
- 437 32. Sherry ST, Ward MH, Kholodov M, *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic*
438 *Acids Res* 2001;29(1):308-11.
- 439 33. Bhattacharya A, Hamilton AM, Furberg H, *et al.* An approach for normalization and quality control
440 for NanoString RNA expression data. *Brief Bioinform* 2020; 10.1093/bib/bbaa163.
- 441 34. Anders S, Huber W. Differential expression analysis for sequence count data. *Genome Biol*
442 2010;11(10):R106.
- 443 35. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq
444 data with DESeq2. *Genome Biol* 2014;15(12):550.
- 445 36. Ding B, Cao C, Li Q, *et al.* Power analysis of transcriptome-wide association study. *bioRxiv* 2020;
446 10.1101/2020.07.19.211151:2020.07.19.211151.
- 447 37. van Iterson M, van Zwet EW, Heijmans BT. Controlling bias and inflation in epigenome- and
448 transcriptome-wide association studies using the empirical null distribution. *Genome Biol* 2017;18(1):19.

- 449 38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
450 Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)*
451 1995;57(1):289-300.
- 452 39. Wheeler HE, Ploch S, Barbeira AN, *et al.* Imputed gene associations identify replicable trans-
453 acting genes enriched in transcription pathways and complex traits. *Genetic Epidemiology*
454 2019;43(6):596-608.
- 455 40. Liu X, Mefford JA, Dahl A, *et al.* GBAT: a gene-based association test for robust detection of
456 trans-gene regulation. *Genome Biology* 2020;21(1):211.
- 457 41. Urbut SM, Wang G, Carbonetto P, *et al.* Flexible statistical methods for estimating and testing
458 effects in genomic studies with multiple conditions. *Nat Genet* 2019;51(1):187-195.
- 459 42. Gravel S. Population genetics models of local ancestry. *Genetics* 2012;191(2):607-19.
- 460 43. Nelson D, Kelleher J, Ragsdale AP, *et al.* Accounting for long-range correlations in genome-wide
461 simulations of large cohorts. *PLoS Genet* 2020;16(5):e1008619.
- 462 44. Shang L, Smith JA, Zhao W, *et al.* Genetic Architecture of Gene Expression in European and
463 African Americans: An eQTL Mapping Study in GENOA. *Am J Hum Genet* 2020;106(4):496-512.
- 464 45. Wang S, Dorsey TH, Terunuma A, *et al.* Relationship between tumor DNA methylation status and
465 patient characteristics in African-American and European-American women with breast cancer. *PLoS*
466 *One* 2012;7(5):e37928.
- 467 46. Conway K, Edmiston SN, Tse CK, *et al.* Racial variation in breast tumor promoter methylation in
468 the Carolina Breast Cancer Study. *Cancer Epidemiol Biomarkers Prev* 2015;24(6):921-30.
- 469 47. Chen Y, Sadasivan SM, She R, *et al.* Breast and prostate cancers harbor common somatic copy
470 number alterations that consistently differ by race and are associated with survival. *BMC Med Genomics*
471 2020;13(1):116.
- 472 48. Parada H, Jr., Sun X, Fleming JM, *et al.* Race-associated biological differences among luminal A
473 and basal-like breast cancers in the Carolina Breast Cancer Study. *Breast Cancer Res* 2017;19(1):131.
- 474 49. Prat A, Adamo B, Cheang MC, *et al.* Molecular characterization of basal-like and non-basal-like
475 triple-negative breast cancer. *Oncologist* 2013;18(2):123-33.

- 476 50. Zhang C, Han Y, Huang H, *et al.* Integrated analysis of expression profiling data identifies three
477 genes in correlation with poor prognosis of triple-negative breast cancer. *Int J Oncol* 2014;44(6):2025-33.
- 478 51. Mahadevappa R, Neves H, Yuen SM, *et al.* DNA Replication Licensing Protein MCM10 Promotes
479 Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast
480 Cancer. *Cancers (Basel)* 2018;10(9).
- 481 52. Hagemann IS. Molecular Testing in Breast Cancer: A Guide to Current Practices. *Arch Pathol*
482 *Lab Med* 2016;140(8):815-24.
- 483 53. Yao Z, Zheng X, Lu S, *et al.* Knockdown of FAM64A suppresses proliferation and migration of
484 breast cancer cells. *Breast Cancer* 2019;26(6):835-845.
- 485 54. Gong D, Ferrell JE, Jr. The roles of cyclin A2, B1, and B2 in early and late mitotic events. *Mol Biol*
486 *Cell* 2010;21(18):3149-61.
- 487 55. Thakkar AD, Raj H, Chakrabarti D, *et al.* Identification of gene expression signature in estrogen
488 receptor positive breast carcinoma. *Biomark Cancer* 2010;2:1-15.
- 489 56. Aguilar H, Urruticoechea A, Halonen P, *et al.* VAV3 mediates resistance to breast cancer
490 endocrine therapy. *Breast Cancer Res* 2014;16(3):R53.
- 491 57. Zeng L, Sachdev P, Yan L, *et al.* Vav3 mediates receptor protein tyrosine kinase signaling,
492 regulates GTPase activity, modulates cell morphology, and induces cell transformation. *Mol Cell Biol*
493 2000;20(24):9212-24.
- 494 58. Rosenblatt AE, Garcia MI, Lyons L, *et al.* Inhibition of the Rho GTPase, Rac1, decreases
495 estrogen receptor levels and is a novel therapeutic strategy in breast cancer. *Endocr Relat Cancer*
496 2011;18(2):207-19.
- 497 59. Xu Z-S, Zhang H-X, Li W-W, *et al.* FAM64A positively regulates STAT3 activity to promote Th17
498 differentiation and colitis-associated carcinogenesis. *Proceedings of the National Academy of Sciences*
499 2019;116(21):10447-10452.
- 500 60. Jiang H, Wang L, Wang F, *et al.* Proprotein convertase subtilisin/kexin type 6 promotes in vitro
501 proliferation, migration and inflammatory cytokine secretion of synovial fibroblast-like cells from
502 rheumatoid arthritis via nuclear κ B, signal transducer and activator of transcription 3 and extracellular
503 signal regulated 1/2 pathways. *Mol Med Rep* 2017;16(6):8477-8484.

- 504 61. Wang QM, Lv L, Tang Y, *et al.* MMP-1 is overexpressed in triple-negative breast cancer tissues
505 and the knockdown of MMP-1 expression inhibits tumor cell malignant behaviors in vitro. *Oncol Lett*
506 2019;17(2):1732-1740.
- 507 62. McGowan PM, Duffy MJ. Matrix metalloproteinase expression and outcome in patients with
508 breast cancer: analysis of a published database. *Ann Oncol* 2008;19(9):1566-72.
- 509 63. Boström P, Söderström M, Vahlberg T, *et al.* MMP-1 expression has an independent prognostic
510 value in breast cancer. *BMC Cancer* 2011;11:348.
- 511 64. Acerbi I, Cassereau L, Dean I, *et al.* Human breast cancer invasion and aggression correlates
512 with ECM stiffening and immune cell infiltration. *Integr Biol (Camb)* 2015;7(10):1120-34.
- 513 65. González LO, Corte MD, Junquera S, *et al.* Expression and prognostic significance of
514 metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. *Hum*
515 *Pathol* 2009;40(9):1224-33.
- 516 66. Xia Y, Fan C, Hoadley KA, *et al.* Genetic determinants of the molecular portraits of epithelial
517 cancers. *Nat Commun* 2019;10(1):5666.

518

519 **FIGURE LEGENDS**

520 **Figure 1.** *Schematic of study analytic approach.* A) In CBCS, constructed race-stratified predictive
521 models of tumor gene expression from *cis*-SNPs. B) In CBCS, imputed GReX at individual-level using
522 genotypes and tested for associations between GReX and CRS in race-stratified linear models; only
523 GReX of genes with significant *cis*- h^2 and high cross validation performance ($R^2 > 0.01$ between observed
524 and predicted expression) considered for race-stratified association analyses. C) Follow-up analyses on
525 TWAS-genes (i.e., genes whose GReX were significantly associated with CRS at FDR <0.10). In race-
526 stratified models, PAM50 SCCs and PAM50 tumor expressions were regressed against TWAS-genes
527 under a Bayesian multivariate regression and multivariate adaptive shrinkage approach.

528

529 **Figure 2.** *Permutation tests and associations between TWAS-genes and CRS for WW and BW.* A) Effect
530 estimates correspond to change in ROR-S, Proliferation score, and ROR-P per one standard deviation
531 increase in TWAS-gene expression (i.e., one standard deviation increase in GReX of gene). Circle

532 denotes a statistically significant association while triangle denotes a non-significant association at
533 significance threshold of p -value <0.05 . Blue denotes WW and red denotes BW. B) Histograms
534 correspond to null distributions of covariates (age at selection, estrogen receptor status, study phase,
535 tumor stage) residualized- R^2 for regressions of CRS on TWAS-genes. Dashed vertical lines correspond to
536 observed covariates residualized- R^2 . Blue denotes WW and red denotes BW.

537


538 **Figure 3.** *Associations between TWAS-genes and PAM50 SCCs.* A) Among WW, associations between
539 TWAS-genes (genes whose GReX was significantly associated with CRS at FDR <0.10) and PAM50
540 SCCs using Bayesian multivariate regression and multivariate adaptive shrinkage. Effect estimates
541 correspond to change in subtype centroid correlations (range -1 to 1) for one standard deviation increase
542 in TWAS-gene expression (i.e., one standard deviation increase in GReX of gene). Circle, triangle, and
543 square denote corresponding FDR intervals for effect sizes. B) Among BW, associations between TWAS-
544 genes and PAM50 SCCs using Bayesian multivariate regression and multivariate adaptive shrinkage.
545 Effect estimates correspond to change in SCCs (range -1 to 1) for one standard deviation increase in
546 TWAS-gene expression (i.e., one standard deviation increase in GReX of gene). Circle, triangle, and
547 square denote corresponding FDR intervals for effect sizes.

548

549 **Figure 4.** *Heatmap of associations between TWAS-genes and PAM50 tumor gene expressions using*
550 *Bayesian multivariate regression and multivariate adaptive shrinkage.* There were 7 TWAS-genes among
551 WW and 1 TWAS-gene among BW. Effect estimates correspond to change in \log_2 normalized PAM50
552 tumor expression for one standard deviation increase in TWAS-gene expression (i.e., one standard
553 deviation increase in GReX of gene). Red denotes positive change in \log_2 normalized tumor expression
554 and blue denotes negative mean change in \log_2 normalized tumor expression. *, **, *** denote FDR
555 intervals for effect sizes. Assignment of PAM50 gene to subtype was based on PAM50 gene centroid
556 values for each subtype; the subtype assigned to a PAM50 gene corresponded to the largest positive
557 centroid value across subtypes for that gene. Importantly, subtype assignment through this “greedy
558 algorithm” are specific to this study and represent a simplified reality (e.g., ESR1 classified as part of
559 Luminal A subtype only even though ESR1 expression correlates with both Luminal A and to a slightly

560 lesser degree Luminal B subtype). Moreover, subtype assignment for this portion of analyses was
561 conducted only for visual comparison of patterns of associations between TWAS-genes and PAM50
562 tumor gene expressions (i.e., subtype assignment in this portion of analyses had no bearing on
563 continuous ROR score calculations or subtype-centroid correlations).

A. Train expression models with CBCS




Train race-stratified models of breast tumor expression using FUSION (Gusev *et al* 2016, Nature Genetics)

B. Perform race-stratified TWAS of ROR scores



Impute GReX (genetically-regulated expression) using individual genotypes from CBCS


Test for associations between GReX and ROR-scores




C. Follow-up on TWAS genes

Bayesian multivariate regression analysis to find associations between GReX and PAM50 gene expression and subtype correlations







medRxiv preprint doi: <https://doi.org/10.1101/2021.03.19.21253983>; this version posted March 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




A)



B)



PAM50 Gene



Mean change in normalized PAM50 gene expression

-0.10.0 0.1

FDR Interval

*** [0,0.001) ** [0.001,0.01) * [0.01,0.05)